Patents by Inventor Katrin Ramsauer
Katrin Ramsauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230111016Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: ApplicationFiled: December 13, 2022Publication date: April 13, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
-
Publication number: 20230110155Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: ApplicationFiled: December 13, 2022Publication date: April 13, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
-
Publication number: 20230116636Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: ApplicationFiled: December 13, 2022Publication date: April 13, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
-
Publication number: 20230111638Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: ApplicationFiled: December 13, 2022Publication date: April 13, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
-
Publication number: 20230105639Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: ApplicationFiled: December 13, 2022Publication date: April 6, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
-
Patent number: 11596645Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: October 27, 2021Date of Patent: March 7, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Publication number: 20220143175Abstract: The present invention provides immunogenic compositions, nucleic acid molecules and VLPs suitable as Norovirus vaccine candidates. Further provided are host cells for producing the biological material as well as methods for producing and/or purifying the immunogenic compositions and VLPs. Further provided is an immunogenic composition for use in methods of preventing/treating a Norovirus infection in a subject.Type: ApplicationFiled: December 30, 2019Publication date: May 12, 2022Inventors: Erich Tauber, Matthias Müllner, Katrin Ramsauer, Sabrina Schrauf, Angelika Irmler, Patrick Csar, David A. Maier, Jochen Stritzker
-
Patent number: 11324770Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: January 13, 2020Date of Patent: May 10, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11291682Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: July 16, 2019Date of Patent: April 5, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Publication number: 20220054525Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: ApplicationFiled: October 27, 2021Publication date: February 24, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
-
Patent number: 11110162Abstract: The present invention relates to the provision of immunogenic or vaccine compositions comprising at least one recombinant Zika virus antigen, wherein the at least one recombinant Zika virus antigen is encoded by at least one nucleic acid sequence encoding at least one E-protein of a Zika virus or a functional fragment thereof. Further provided are nucleic acid molecules and a recombinant chimeric virus encoding and/or comprising selected antigens from a Zika virus, which are suitable as vaccine compositions. Preferably, the sequences encoding at least one Zika virus antigens suitable for eliciting an immune response are operably linked to a non-flavivirus derived vector backbone. Further provided are methods for purifying the recombinant chimeric virus particles or the immunogenic composition. Finally, there is provided an immunogenic/vaccine composition for use in a method of preventing or treating a Zika virus disease.Type: GrantFiled: December 23, 2016Date of Patent: September 7, 2021Assignee: THEMIS BIOSCIENCE GMBHInventors: Erich Tauber, Sabrina Schrauf, Matthias Müllner, Katrin Ramsauer, Angelika Irmler, Patrick Csar
-
Publication number: 20210268013Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: ApplicationFiled: May 14, 2021Publication date: September 2, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
-
Publication number: 20210254021Abstract: Provided is a method for producing and/or purifying measles virus (MV) particles from a sample, the method comprising in sequential order the following steps loading a sample containing MV particles and one or more impurities onto a stationary phase material for carrying out flow-through chromatography to bind at least a fraction of the impurities contained in the sample and to produce a flow-through comprising at least a fraction of the MV particles contained in the sample; carrying out filtration, preferably ultrafiltration, and obtaining a retentate having an increased MV titer relative to the MV titer comprised in the flow-through. Further provided is a system for producing and/or purifying MV particles, comprising at least one bioreactor; a clarification unit, preferably a dead end filter unit, downstream to the bioreactor; a flow through chromatography unit downstream to the clarification unit; and a filtration unit, downstream to the flow through chromatography unit.Type: ApplicationFiled: June 14, 2019Publication date: August 19, 2021Inventors: Patrick CSAR, Alois JUNGBAUER, Alexander KORT, Matthias MÜLLNER, Dieter PALMBERGER, Katrin RAMSAUER, Sabrina SCHRAUF, Petra STEPPERT, Erich TAUBER, David A. MAIER, Jochen STRITZKER
-
Patent number: 11026964Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: August 30, 2017Date of Patent: June 8, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Mandl
-
Patent number: 10894079Abstract: The present invention provides purification strategies for sterically demanding, i.e. large and pleomorphic, infectious virus particles or VLPs derived therefrom, preferably having a measles virus scaffold to yield fractions or compositions with a significantly reduced content of contaminating host cell DNA and a reduced content of further process-related impurities. Further provided are methods of propagating and purifying infectious virus particles having a measles virus scaffold suitable to provide a preparation having a strongly reduced content of contaminating host cell DNA and a reduced content of further process-related impurities for immunogenic or anti-tumor purposes. In addition, immunogenic and vaccine compositions based on the above methods are provided. Finally, there are provided immunogenic or vaccine compositions produced by the disclosed methods, which are suitable for use in immunogenic or prophylactic vaccination treatment of a subject in need thereof.Type: GrantFiled: December 23, 2016Date of Patent: January 19, 2021Assignee: THEMIS BIOSCIENCE GMBHInventors: Matthias Müllner, Erich Tauber, Patrick Csar, Angelika Irmler, Katrin Ramsauer, Sabrina Schrauf
-
Publication number: 20200323896Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: ApplicationFiled: January 13, 2020Publication date: October 15, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
-
Patent number: 10532067Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: October 5, 2017Date of Patent: January 14, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Publication number: 20190343862Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: ApplicationFiled: July 16, 2019Publication date: November 14, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Publication number: 20190083601Abstract: The present invention relates to the provision of immunogenic or vaccine compositions comprising at least one recombinant Zika virus antigen, wherein the at least one recombinant Zika virus antigen is encoded by at least one nucleic acid sequence encoding at least one E-protein of a Zika virus or a functional fragment thereof. Further provided are nucleic acid molecules and a recombinant chimeric virus encoding and/or comprising selected antigens from a Zika virus, which are suitable as vaccine compositions. Preferably, the sequences encoding at least one Zika virus antigens suitable for eliciting an immune response are operably linked to a non-flavivirus derived vector backbone. Further provided are methods for purifying the recombinant chimeric virus particles or the immunogenic composition. Finally, there is provided an immunogenic/vaccine composition for use in a method of preventing or treating a Zika virus disease.Type: ApplicationFiled: December 23, 2016Publication date: March 21, 2019Inventors: Erich Tauber, Sabrina Schrauf, Matthias Müllner, Katrin Ramsauer, Angelika Irmler, Patrick Csar
-
Publication number: 20180371426Abstract: The present invention provides purification strategies for sterically demanding, i.e. large and pleomorphic, infectious virus particles or VLPs derived therefrom, preferably having a measles virus scaffold to yield fractions or compositions with a significantly reduced content of contaminating host cell DNA and a reduced content of further process-related impurities. Further provided are methods of propagating and purifying infectious virus particles having a measles virus scaffold suitable to provide a preparation having a strongly reduced content of contaminating host cell DNA and a reduced content of further process-related impurities for immunogenic or anti-tumor purposes. In addition, immunogenic and vaccine compositions based on the above methods are provided. Finally, there are provided immunogenic or vaccine compositions produced by the disclosed methods, which are suitable for use in immunogenic or prophylactic vaccination treatment of a subject in need thereof.Type: ApplicationFiled: December 23, 2016Publication date: December 27, 2018Inventors: Matthias Müllner, Erich Tauber, Patrick Csar, Angelika Irmler, Katrin Ramsauer, Sabrina Schrauf